Your First Refill and GLP-1 Dose Increase

Write down your medication, formulation, prescribed dose and recent dose dates. Include missed doses, appetite changes, symptoms and how treatment affects ordinary eating and drinking. A useful update describes both benefits and problems rather than focusing only on the scale or asking for the next higher dose.

Tell your clinician about new prescriptions, pregnancy plans, upcoming procedures and any change in your health. If the supply seems to be running out unexpectedly, contact the care team instead of stretching doses or drawing extra medication from another vial. Refill planning is an opportunity to verify that the medication amount, measurement and timing all match your prescription. See how Join Luma works for the distinction between clinical review and shipping.

No. The clinician decides whether an increase is appropriate based on your treatment response, tolerability and prescription. Persistent nausea, vomiting, inability to eat normally or other symptoms deserve discussion before an escalation. A larger dose is not automatically a better next step, and a refill date is not independent permission to change the amount.

Stay with the instructions you have been given until the care team provides updated directions. If the new label differs from your understanding, ask for clarification before using it. Do not try to catch up after a missed week by taking extra medication or shorten intervals to reach a maintenance dose sooner. A clear written plan is especially useful when the refill and dose-change dates do not coincide.

The Wegovy prescribing information describes starting the FDA-approved injection at a low dose and escalating in four-week steps. It also includes guidance about tolerability and missed doses. These are instructions for Wegovy, not a Join Luma compounded semaglutide titration schedule.

Your clinician and prescription label determine your compounded medication directions. Do not copy an online brand-dose chart onto your vial or assume that a new shipment means you have reached the next step. If you are prescribed a once-daily oral ODT tablet, injection escalation tables are not its instructions. Ask what dose you should use now, when the clinician expects to reassess it and what symptoms would change that plan.

The Zepbound prescribing information describes increasing the FDA-approved brand dose in 2.5 mg increments after at least four weeks at a dose until an appropriate maintenance dose is reached. It directs considering response and tolerability when selecting maintenance treatment. “At least” matters: it is not a command to increase every four weeks regardless of symptoms.

This is brand-product context, not an independently usable schedule for compounded tirzepatide. It also does not establish a dose conversion from semaglutide. If you are changing medication or restarting after an interruption, tell the clinician before the refill is finalized. The right next prescription depends on the treatment history, not just which vial size or dose a previous provider supplied.

The FDA’s dosing-error alert describes mistakes involving different concentrations and confusion between milligrams, milliliters and syringe units. Read the label on each new vial, even when the medication name looks familiar. Ask the clinician or dispensing pharmacy to confirm any measurement you cannot confidently explain back.

A higher concentration can deliver the same milligram amount in less volume. Never carry forward the old units by habit. VialsRx concentrations are not published; your label lists the concentration. Hallandale also has more than one concentration, so a pharmacy name alone is not enough to identify the measurement.

Join Luma uses the same price at every dose within your plan. Plans include clinician oversight, medication if prescribed, necessary supplies and shipping, with no membership fees. A prescribed increase does not itself raise that plan price; changing medication, commitment length or patient pricing category is a separate billing question.

New patients starting a three-month plan pay $99/month for compounded semaglutide or $149/month for compounded tirzepatide. This starting price applies to the first plan period and is designed to help people new to GLP-1 medication get started. Plans then renew at affordable Current GLP User pricing for the same commitment length: $119/month for semaglutide or $179/month for tirzepatide on three-month plans.

Monthly Current GLP User options are $149 for semaglutide and $219 for tirzepatide. Review current plan pricing before renewal so you compare the correct commitment length. The first clinical refill and the end of your paid plan period are not necessarily the same event, so check your actual billing date rather than assuming every shipment starts a new plan.

Check the amount remaining, the beyond-use date and your next scheduled dose, then contact support early if the timing looks uncertain. Free expedited 2-day shipping applies once medication is dispensed; it does not include any time needed for clinical questions or pharmacy processing. Do not change your dose merely to fit a delivery estimate.

To change commitment length, contact support before the next billing date. For a pause or refill-date change, ask what is possible and obtain confirmation; there is no published policy promising those changes. Six-month plans ship medication in supplies of up to three months. Read how to manage your Join Luma plan before making cancellation or shipment assumptions.

Support is available 24/7 at support@joinluma.com or through the patient portal; most inquiries receive a reply within 1–2 hours. That is a typical support response window, not a guarantee of clinician review or an emergency service. Ask support to help route medical questions to your clinician rather than treating a billing reply as dosing authorization.

Tell your clinician the exact last dose date and how many scheduled doses were missed before using a new supply. Restart instructions differ between products, and a refill authorization does not mean an old dose remains appropriate after a prolonged break. See continuing a current dose for the brand-label distinction.

Seek urgent care for severe abdominal pain, signs of pancreatitis, significant dehydration, or a serious allergic reaction; call 911 for a life-threatening emergency. Do not wait for a portal reply in an emergency. For nonurgent nausea, constipation, appetite changes or uncertainty about the next dose, contact your clinician for a plan tailored to your symptoms.

The FDA’s compounding explanation also clarifies why brand approval and trial findings should not be treated as evidence of equivalent results for your compounded prescription. Keep questions focused on your actual product, label and care plan.